Valproate — The HDAC Inhibitor and Mood Stabilizer
Valproate is a widely used anticonvulsant and mood stabilizer that also functions as a histone deacetylase (HDAC) inhibitor. In preclinical models, its epigenetic effects have been shown to extend lifespan and clear senescent cells, making it a molecule of interest in longevity research.
Mechanism of Action
Valproate (valproic acid) is a short-chain fatty acid that acts as a broad-spectrum inhibitor of class I and IIa histone deacetylases (HDACs). By inhibiting HDACs, it promotes chromatin remodeling and hyperacetylation of histones, altering gene expression profiles. This epigenetic modulation has been linked to lifespan extension in model organisms, potentially through interactions with the insulin/IGF-1 signaling pathway. Additionally, valproate exhibits senolytic properties by selectively inducing apoptosis in senescent cells.
Human Trial Evidence
No published human longevity trials. Animal/in-vitro evidence only. Valproate has been shown to extend lifespan in C. elegans and selectively induce apoptosis in senescent cells in vitro.
Dosing Protocol
10-15 mg/kg/day is the typical starting dose for epilepsy or bipolar disorder, often titrated up to 60 mg/kg/day. Longevity dosing in humans is unestablished. Prescription required.
Safety & Contraindications
Common adverse effects include gastrointestinal distress, weight gain, and tremor. Valproate carries black box warnings for hepatotoxicity, teratogenicity (neural tube defects), and pancreatitis. It is contraindicated in patients with hepatic disease or mitochondrial disorders. Prescription required.